Antidepressant Tx Increases Subsequent Mania/Bipolar Risk

This article originally appeared here.
Share this content:
Antidepressant Tx Increases Subsequent Mania/Bipolar Risk
Antidepressant Tx Increases Subsequent Mania/Bipolar Risk

WEDNESDAY, Dec. 16, 2015 (HealthDay News) -- For patients with unipolar depression, the risk of subsequent mania/bipolar disorder is increased in association with antidepressant treatment, according to a study published online Dec. 14 in BMJ Open.

Rashmi Patel, B.M., B.Ch., from King's College London, and colleagues examined the correlation between antidepressant therapy and later onset of mania/bipolar disorder in a retrospective cohort study. Data were reviewed for 21,012 adults presenting to the South London and Maudsley National Health Service Trust with unipolar depression between April 1, 2006, and March 31, 2013.

The researchers found that the overall incidence rate of mania/bipolar disorder was 10.9/1,000 person-years. The peak incidence of mania/bipolar disorder was observed in patients aged 26 to 35 years (12.3 per 1,000 person-years). There was a correlation between prior antidepressant treatment with increased incidence of mania/bipolar disorder, varying from 13.1 to 19.1 per 1,000 person-years. Significant correlations were seen for selective serotonin reuptake inhibitors and venlafaxine (hazard ratios, 1.34 and 1.35, respectively).

"In people with unipolar depression, antidepressant treatment is associated with an increased risk of subsequent mania/bipolar disorder," the authors write. "These findings highlight the importance of considering risk factors for mania when treating people with depression."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »